[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 683
Citations 0
News From the Food and Drug Administration
April 4, 2017

Biologic Medication for Psoriasis

JAMA. 2017;317(13):1308. doi:10.1001/jama.2017.2408

The FDA has approved a new biologic medication for patients with moderate to severe plaque psoriasis. Brodalumab, marketed as Siliq, is indicated for patients who are candidates for systemic therapy or phototherapy and aren’t responding to other systemic therapies.

Because the drug has been linked with suicidal ideation and behavior, including completed suicides, the FDA added a boxed warning to its label. The drug is available only through a restricted program that requires prescribers to register and to counsel patients about the risk. Pharmacies that dispense brodalumab also must register with the program.